X

Due to the lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at http://www.usa.gov.
NIH Guide: PREPARATION OF IMMUNOCONJUGATES

PREPARATION OF IMMUNOCONJUGATES

NIH GUIDE, Volume 22, Number 7, February 19, 1993



RFP AVAILABLE:  NCI-CM-37843-37



P.T. 34



Keywords:

  Cancer/Carcinogenesis 

  Monoclonal Antibodies 



National Cancer Institute



The Biological Resource Branch of the Biological Response Modifiers

Program Division of Cancer Treatment, National Cancer Institute

(NCI), is interested in receiving proposals from, and establishing

Master Agreements with, offerors who have the capability in

Preparation of Immunoconjugates.  The purpose of this procurement is

to prepare various preclinical and clinical grade monoclonal

antibodies/targeting agents with ligands such as chelating agents,

toxins, cytotoxic agents, or other targeting molecules.  Although the

NCI wishes to be flexible in the nature of their request, it is

primarily interested in the preparation of immunoconjugates including

monoclonal antibody chelates, that can bind various radionuclides and

immunotoxins.  Monoclonal antibodies (or other targeting agents)

supplied by the NCI will be chemically conjugated to various ligands

such as chelating agents and toxins using procedures that have

appeared in peer-reviewed journals.  It is anticipated that the

offeror will prepare milligram quantities (approximately 50 to 1000

mg) each of purified ligand conjugated monoclonal antibodies,

antibody fragments, or other targeting molecules as specified by the

NCI under conditions of GLP and/or GMP.  The offeror will evaluate

these immunoconjugates for purity, stability, immuno-reactivity, and

other criteria as specified by the NCI for their potential as

diagnostic and/or therapeutic agents.  Multiple awards may be made to

qualified offerors responding to this RFP.



Master Agreement Announcement (MAA) No. NCI-CM-37843-37 will be

issued upon request on or about March 1, 1993 and proposals will be

due approximately six weeks after issuance of the MAA.



INQUIRIES



To obtain a copy of MAA No. NCI-CM-37843-37 send a written request

to:



Ms. Patricia Lightner

Research Contracts Branch

National Cancer Institute

Executive Plaza South, Room 603

Rockville, MD  20852

Telephone:  (301) 496-8020



No collect calls will be accepted.



.


Return to 1993 Index

Return to NIH Guide Main Index


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.